Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pediococcus acidilactici CCFM6432
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pediococcus acidilactici CCFM6432 is a specific probiotic strain developed by researchers at Jiangnan University as a live biotherapeutic product (LBP) or psychobiotic. It is primarily investigated for the treatment of major depressive disorder (MDD), with a specific focus on alleviating anhedonia, a symptom often resistant to standard antidepressants. The strain functions by modulating the gut-brain axis and has been shown in clinical trials to improve clinical scores (HAMD, TEPS) and electroencephalography (EEG) biomarkers like stimulus-preceding negativity (SPN) when used as an adjunctive therapy. It is preserved under the number GDMCC No. 60638.
- Other names
- Pediococcus acidilactici CCFM6432P. acidilactici CCFM6432GDMCC No. 60638
Beyond the preview
Go deeper on pediococcus acidilactici CCFM6432.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pediococcus acidilactici CCFM6432.